Home・Список акций・Relay Therapeutics Inc

Relay Therapeutics Inc

Закрыт

СекторЗдравоохранение

19.61 -0.15

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

18.48

Макс.

19.8

Ключевые показатели
By Trading Economics
Доход	-18M -73M
Продажи	-4M 3M
Прибыль на акцию	-0.41
Рентабельность продаж	-2,443.033
Сотрудники	193
EBITDA	-15M -73M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+28.1% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	1.6B 4.1B
Предыдущая цена открытия	19.76
Предыдущая цена закрытия	19.61

Новостные настроения

By Acuity

50%

168 / 340 Рейтинг в Healthcare

Relay Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 авг. 2026 г., 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 авг. 2026 г., 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 авг. 2026 г., 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 авг. 2026 г., 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 июл. 2026 г., 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 июл. 2026 г., 17:36 UTC

Correlated Moves

News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 июл. 2026 г., 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 июл. 2026 г., 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 июл. 2026 г., 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 июл. 2026 г., 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 июл. 2026 г., 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 июл. 2026 г., 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Сравнение c конкурентами

Изменение цены

Relay Therapeutics Inc Прогноз

Целевая цена

By TipRanks

28.1% рост

Прогноз на 12 месяцев

Средняя 25.3 USD 28.1%

Максимум 31 USD

Минимум 20 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для Relay Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

12 ratings

Покупка

Удержание

Продажа

Основано на мнении 12 аналитиков, присваивавших рейтинги акциям Relay Therapeutics Inc – Данные за последние 3 месяца.

Настроения

By Acuity

168 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.